Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.56 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528935 | 0.87 | KDR (0.84) | KDRABCB1 | |
| SCHEMBL429452 | 0.85 | KDR (1.00) | KDRRETMAP3K20RIPK3ABCB1 | |
| SCHEMBL6104034 | 0.82 | KDR (0.64) | KDRRETMAP3K20RIPK3PDPK1 | |
| SCHEMBL428954 | 0.80 | KDR (0.70) | KDRPDPK1 | |
| Hydrochloric Acid SCHEMBL448725 | 0.79 | KDR (0.86) | KDRRETMAP3K20RIPK3ABCB1 | |
| SCHEMBL7277038 | 0.78 | ATM (0.67) | EGLN1ATM | |
| SCHEMBL18049007 | 0.77 | PDPK1 (0.64) | KDRRETMAP3K20RIPK3PDPK1 | |
| SCHEMBL18048938 | 0.77 | KDR (0.69) | KDR | |
| SCHEMBL3115327 | 0.77 | KDR (0.74) | KDRRETMAP3K20RIPK3ABCB1 | |
| SCHEMBL1715912 | 0.76 | KDR (0.64) | KDREGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885RET 1473/4885MAP3K20 2244/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885RET 1473/4885MAP3K20 2244/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885RET 1473/4885MAP3K20 2244/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDR 18/4885RET 1473/4885MAP3K20 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.